title: In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme.
abstract: This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC(90) against ESBL-producing K. pneumoniae isolates was 2 microg/ml. Besides, doripenem with the MIC(90) of 0.5 microg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.
authors.affiliation: Department of Intensive Care Units, Min-Sheng General Hospital, Taoyuan County, Taiwan.
authors.forename: S-S
authors.initials: SS
authors.lastname: Jean
authors.forename: P-R
authors.initials: PR
authors.lastname: Hsueh
authors.forename: W-S
authors.initials: WS
authors.lastname: Lee
authors.forename: H-T
authors.initials: HT
authors.lastname: Chang
authors.forename: M-Y
authors.initials: MY
authors.lastname: Chou
authors.forename: I-S
authors.initials: IS
authors.lastname: Chen
authors.forename: J-H
authors.initials: JH
authors.lastname: Wang
authors.forename: C-F
authors.initials: CF
authors.lastname: Lin
authors.forename: J-M
authors.initials: JM
authors.lastname: Shyr
authors.forename: W-C
authors.initials: WC
authors.lastname: Ko
authors.forename: J-J
authors.initials: JJ
authors.lastname: Wu
authors.forename: Y-C
authors.initials: YC
authors.lastname: Liu
authors.forename: W-K
authors.initials: WK
authors.lastname: Huang
authors.forename: L-J
authors.initials: LJ
authors.lastname: Teng
authors.forename: C-Y
authors.initials: CY
authors.lastname: Liu
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001424:Bacterial Infections / Q000382:microbiology*; D015780:Carbapenems / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000382:microbiology*; D003428:Cross Infection / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006784:Hospitals, Teaching; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D013624:Taiwan
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems